Key Takeaways for Humana Stock as of August 2026
- Broad-Based Beat: Humana posted Q2 revenue of $40.87B (0.72% above the $40.57B Street estimate) and adjusted EPS of $7.61 versus the $7.00 estimate, an 8.79% beat that also marked 21.37% YoY growth.
- Cash Flow Surge: Operating cash flow hit $1,966M, 183.17% above the $694.28M estimate, while free cash flow of $1,834M beat estimates by 75.17% and grew 58.51% YoY.
- Sequential Margin Slide: EBITDA margin fell 118bps QoQ to 3.91% and adjusted EPS dropped 26.19% QoQ from $10.31 to $7.61, even as GAAP EPS of $5.73 missed the $7.13 estimate by 19.67%.
- 2028 Margin Pledge: CEO Jim Rechtin tied the entire 2027 bid strategy to one number, telling investors the top priority was “the necessary margin progression to remain on track to deliver our ’28 commitment of returning to a sustainable margin of at least 3%.”
HUM Stock Investors Get a Beat-Heavy Quarter With a Margin Warning Baked In
Humana (HUM) stock traders got a mixed signal out of the company’s second-quarter print for the period ended June 30, 2026. Revenue came in at $40.87 billion against a $40.57 billion Street estimate, a narrow 0.72% beat, but the number that mattered more was underneath it. Adjusted EPS of $7.61 topped the $7.00 estimate by 8.79% and climbed 21.37% year over year, yet it fell 26.19% from the $10.31 posted just one quarter earlier. That sequential drop shows up across the income statement: EBITDA margin compressed 118 basis points quarter over quarter to 3.91%, and EBIT margin gave back 110 basis points to 3.33%.
Management framed that compression as the cost of a longer fix.
On the call, CEO Jim Rechtin laid out the company’s four operating drivers, product and experience, clinical excellence, efficient operations, and CenterWell and Medicaid growth, then zeroed in on the bid strategy for 2027. That plan will cost Humana members: roughly 600,000 are expected to be affected by targeted plan exits, though the company says it recaptured just over 40% of a similar cohort in 2025. Rechtin was direct about why the company is taking that hit now, telling investors on the Q2 earnings call: “Our #1 priority in MA bids was to make the necessary margin progression to remain on track to deliver our ’28 commitment of returning to a sustainable margin of at least 3%.” That statement anchors the entire quarter. Everything else, the Stars metric improvements CFO Celeste Mellet cited across 11 of 12 tracked HEDIS measures, the 120 basis point year-over-year drop in the operating cost ratio, the $900 million Gentiva divestiture funding the MaxHealth acquisition, exists to build toward that single 2028 target.
Cash generation told a cleaner story. Operating cash flow of $1,966 million beat estimates by 183.17%, and free cash flow of $1,834 million came in 75.17% ahead of the $1,047 million estimate, up 58.51% year over year. Inpatient costs also showed favorability, with both lower admits per 1,000 and lower unit costs, concentrated in members tied to value-based providers. That combination, cash strength alongside margin compression, is what Humana stock holders are pricing through the rest of 2026.
TIKR Values HUM Stock at $592, Pricing In a Multiyear Margin Recovery
TIKR’s mid-case model values Humana stock at $592 by the end of 2030, implying a 63% total return from the current price of $364, or 12% annualized over 4.4 years.
That annualized return sits well above what a typical large-cap health insurer offers a buy-and-hold investor over a multiyear horizon, reflecting a stock still working through a depressed margin base rather than one already re-rated to peak profitability. The model’s return profile assumes Humana closes a meaningful gap between where its Medicare Advantage margins sit today and the 3% sustainable pretax margin management has committed to by 2028.
That target is reachable because the mechanics management described on the call point in the same direction: plan exits designed to protect the highest-return business, an operating cost ratio already down 120 basis points year over year, and Stars metric improvement across 11 of 12 tracked measures heading into bonus year 2028. Each of those levers chips away at the margin gap the TIKR model is pricing Humana stock to close.
Should You Invest in Humana Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Humana Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Humana Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HUM stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
